Free Trial

Top 3 Stocks Seeing a Spike in Call Option Volume

Stuttgart, Germany - 07-21-2024: Person holding cellphone with webpage of Canadian uranium mining company Cameco Corporation in front of logo. Focus on center of phone display. — Stock Editorial Photography

Key Points

  • Three stocks reported unusual call option volume this month and the reasons why would make sense to all investors and Wall Street analysts.
  • The fundamental story behind these stocks would justify catalysts in the near future.
  • According to analysts, there is now double-digit upside pending in these stocks and their future upside.
  • Five stocks we like better than SPDR S&P Regional Banking ETF.

Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today’s concept of analysis. However, most investors fail to realize that these indicators and patterns are nothing more than price action recognition, and what drives price action is volume.

So, at the end of the day, those who understand volume understand where and when a stock or exchange-traded fund (ETF) might start to move. Today, it isn’t just any regular volume that stands out; it is call option volume, which is important due to its implications for the underlying stocks. Call options only pay off if a stock moves to a certain price by a certain date. Higher stakes mean higher conviction levels.

This is why investors can expect high conviction in upswings for stocks like Cameco Co. NYSE: CCJ in the basic materials sector as a uranium play or healthcare sector discounted giant Pfizer Inc. NYSE: PFE and even a broader ETF covering the regional banks through the SPDR S&P Regional Banking ETF NYSEARCA: KRE. There are plenty of reasons to justify the rising volume in these bullish bets; here are some of them,

Cameco: Technology Trends Need Uranium to Work

Cameco Today

Cameco Co. stock logo
CCJCCJ 90-day performance
Cameco
$50.30 +2.85 (+6.01%)
As of 02/4/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
52-Week Range
$35.43
$62.55
Dividend Yield
0.24%
P/E Ratio
264.76
Price Target
$66.56

There is a reason why the biggest names in the technology sector, Amazon.com Inc. NASDAQ: AMZN, Alphabet Inc. NASDAQ: GOOGL, and other giants, are now betting on nuclear energy. Today’s energy grid just won’t be able to withstand the demand from new computing developments.

Artificial intelligence is one theme that carries its own set of energy demands. However, it is still limited in comparison to what’s next, which is quantum computing. Nuclear energy seems to be the most viable solution as these technologies become more developed and adopted in the global economy.

This is why call option traders have run into Cameco stock in recent weeks, netting a volume of up to 384,705 total call options traded in the stock. More than that, Wall Street analysts now see a consensus price target on Cameco of up to $66.6 a share to call for a net upside of 30% from where the stock trades today.

These trends also explain the 9.3% collapse in short interest for the company over the past month, a clear sign of bearish capitulation in the run-up to these bullish themes for the entire industry.

Pfizer Stock’s Discount Won’t Last Long

Pfizer Today

Pfizer Inc. stock logo
PFEPFE 90-day performance
Pfizer
$25.88 -0.32 (-1.24%)
As of 02/4/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
52-Week Range
$24.48
$31.54
Dividend Yield
6.65%
P/E Ratio
34.97
Price Target
$31.92

By trading at a significant discount to its 2022 highs, Pfizer stock now offers investors a rare opportunity to buy this industry giant at a discount. Besides the price action, discounts are coming through the company’s valuation multiples, such as the price-to-book (P/B) of 1.7x compared to the medical sector’s average of 4.8x today.

As of December 2024, traders bought up to 201,090 call options, which was unusual compared to the usual volume of 157,196 for Pfizer stock. This action confirms that the stock is not only cheap but that a catalyst might be underway in the near future to deliver these higher prices.

To build on top of these bullish trends, analysts at Guggenheim have kept their buy rating on Pfizer stock as of December 2024, this time placing a $33 price target on it as well. This valuation would imply a net upside of 25% from where it sits today.

In addition to these trends, investors can notice the 5.5% decline in Pfizer stock’s short interest over the past month, perhaps as bearish traders see the same catalyst and upside that these call option buyers have noticed to justify their unusual volume purchases.

Regional Banks Set to Soar on Rate Cuts?

SPDR S&P Regional Banking ETF Today

SPDR S&P Regional Banking ETF stock logo
KREKRE 90-day performance
SPDR S&P Regional Banking ETF
$64.05 +1.22 (+1.94%)
As of 02/4/2025 04:10 PM Eastern
52-Week Range
$45.46
$70.25
Dividend Yield
2.30%
Assets Under Management
$4.90 billion

There are reasons to believe that bonds will rally in the coming months, especially as the Federal Reserve (the Fed) is starting to cut rates and looking to keep doing so into 2025. These lower rates help assets like regional banks see a spike in earnings due to business activity.

Through products like mortgages, credit cards, and auto loans, these regional banks could see better earnings per share (EPS) in the coming months, which could easily translate into higher valuations for most of these stocks as well.

On top of the upside that these call option buyers see in regional banks, the SPDR S&P Regional Banking ETF offers a $1.47 payout per share to translate into a 2.42% dividend yield today.

Should You Invest $1,000 in SPDR S&P Regional Banking ETF Right Now?

Before you consider SPDR S&P Regional Banking ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SPDR S&P Regional Banking ETF wasn't on the list.

While SPDR S&P Regional Banking ETF currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Gabriel Osorio-Mazilli
About The Author

Gabriel Osorio-Mazilli

Contributing Author

Value Stocks, Asian Markets, Macro Economics

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
SPDR S&P Regional Banking ETF (KRE)N/A$64.05+1.9%2.30%8.36Moderate Buy$64.05
Cameco (CCJ)
4.5992 of 5 stars
$50.30+6.0%0.24%264.76Buy$66.56
Pfizer (PFE)
4.9541 of 5 stars
$25.88-1.2%6.65%34.97Moderate Buy$31.92
Amazon.com (AMZN)
4.8053 of 5 stars
$242.06+2.0%N/A51.83Moderate Buy$252.56
Alphabet (GOOGL)
3.992 of 5 stars
$206.38+2.6%0.39%27.37Moderate Buy$211.00
SPDR S&P Regional Banking ETF (KRE)N/A$64.05+1.9%2.30%8.36Moderate Buy$64.05
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Palantir’s Explosive Growth: Buy Now or Wait for a Dip?
5 Stocks to BUY NOW in February 2025
How To Invest in Crypto as A Complete BEGINNER in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines